Protoporphyrin IX: the Good, the Bad, and the Ugly

Sachar, Madhav; Anderson, Karl E.; Ma, Xiaochao

doi:10.1124/jpet.115.228130

Cited by 189 publications

(186 citation statements)

References 155 publications

(154 reference statements)

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…The initiation of cell stress can be triggered by the accumulation of a heme biosynthesis intermediate, pro-toporphyrin IX (PPIX) in the liver. PPIX accumulation is associated with hepatotoxic effects mediated by the blocking of bile acid efflux [32, 33]. The liver is responsible for the biosynthesis of 15% of heme in the body [34].…”

Section: Specific Molecular Mechanisms Of Isoniazid/rifampicin-inducementioning

confidence: 99%

Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Bao

Rasmussen

et al. 2018

Curr Pharmacol Rep

View full text Add to dashboard Cite

Purpose of this Review In order to combat the development of drug resistance, the clinical treatment of tuberculosis requires the combined use of several anti-tuberculosis (anti-TB) drugs, including isoniazid and rifampicin. Combinational treatment approaches are suggested by the World Health Organization (WHO) and are widely accepted throughout the world. Unfortunately, a major side effect of the treatment is the development of anti-tuberculosis drug-induced liver injury (AT-DILI). Many factors contribute to isoniazid- and rifampicin-mediated AT-DILI and genetic variations are among the most common factors. The purpose of this review is to provide information on genetic variations associated with isoniazid- and rifampicin-mediated AT-DILI. Recent Findings The genetic variations associated with AT-DILI have been identified in the genomic regions within or near genes encoding proteins in the following pathways: drug metabolizing enzymes (NAT2, CYP2E1, and GSTs), accumulation of bile acids, lipids, and heme metabolites (CYP7A1, BSEP, UGTs, and PXR), immune adaptation (HLAs and TNF-α), and oxidant challenge (TXNRD1, SOD1, BACH1, and MAFK). Summary The information summarized in this review considers the genetic bases of risk factors contributing to AT-DILI and provides information that may help for future studies. Some of the implicated genetic variations can be used in the design of genetic tests and serve as biomarkers for the prediction of isoniazid- and rifampicin-mediated AT-DILI risk in personalized medicine.

show abstract

Section: Specific Molecular Mechanisms Of Isoniazid/rifampicin-inducementioning

confidence: 99%

Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Bao

Rasmussen

et al. 2018

Curr Pharmacol Rep

View full text Add to dashboard Cite

show abstract

“…4 PPIX is an intermediate in the heme biosynthesis pathway and its accumulation is the primary cause of liver injury in patients suffering from erythropoietic protoporphyria. 5–7 Rifampicin is a human PXR ligand that induces delta-aminolevulinate synthase 1 (ALAS1), the rate-limiting enzyme regulating heme and porphyrin biosynthesis. 8 However, the role of INH in PPIX accumulation caused by INH and rifampicin co-therapy remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Chronic Treatment with Isoniazid Causes Protoporphyrin IX Accumulation in Mouse Liver

Sachar

Liu

et al. 2016

Chem. Res. Toxicol.

View full text Add to dashboard Cite

Isoniazid (INH) can cause hepatotoxicity. In addition, INH is contraindicated in patients suffering from porphyrias. Our metabolomic analysis revealed that chronic treatment with INH in mice causes a hepatic accumulation of protoporphyrin IX (PPIX). PPIX is an intermediate in the heme biosynthesis pathway and it is also known as a hepatotoxin. We further found that INH induces delta-aminolevulinate synthase 1 (ALAS1), the rate-limiting enzyme in heme biosynthesis. We also found that INH downregulates ferrochelatase (FECH), the enzyme that converts PPIX to heme. In summary, this study illustrated that chronic treatment with INH causes PPIX accumulation in mouse liver in part through ALAS1 induction and FECH downregulation. This study also highlights that drugs can disrupt the metabolic pathways of endobiotics and increase the risk of liver damage.

show abstract

“…It has been shown that chronic treatment of mice with INH causes protoporphyrin IX accumulation in the liver, together with the induction of ALAS1 and downregulation of ferrochelatase (Sachar et al, 2016). As depicted in Fig.…”

Section: Chronic Effect Of Drugs On Heme Metabolismmentioning

confidence: 89%

“…On the other hand, protoporphyrin IX-based strategies have been employed for cancer diagnosis and treatment. In this respect, the recently published review by Sachar et al (2016) examines physiological and pathological activities of protoporphyrin IX.…”

Section: Chronic Effect Of Drugs On Heme Metabolismmentioning

confidence: 99%

“…In addition, a new insight has postulated that HO systems possess non-canonical functions with enzymatic activities, such as shaperon-like roles in protein-protein interactions with P450s and others, and roles in intracellular compartmentalization and extracellular excretion (Vanella et al, 2016). In addition, reviews have appeared on the beneficial and unfavorable evaluation of physiological and pathological roles played by protoporphyrin IX, intermediates of heme synthesis (Sachar et al, 2016) and bilirubin, a heme degradation product (Zahir et al, 2015), in the body. Interestingly, Gao et al (2017) most recently reported that plasma HO-1 is a potential hepatotoxic biomarker in rats when examined for acetaminophen-induced hepatotoxicity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chemical-induced coordinated and reciprocal changes in heme metabolism, cytochrome P450 synthesis and others in the liver of humans and rodents

2016

View full text Add to dashboard Cite

-A wide variety of drugs and chemicals have been shown to produce induction and inhibition of heme-metabolizing enzymes, and of drug-metabolizing enzymes, including cytochrome P450s (P450s, CYPs), which consist of many molecular species with lower substrate specificity. Such chemically induced enzyme alterations are coordinately or reciprocally regulated through the same and/or different signal transductions. From the toxicological point of view, these enzymatic changes sometimes exacerbate inherited diseases, such as precipitation of porphyrogenic attacks, although the induction of these enzymes is dependent on the animal species in response to the differences in the stimuli of the liver, where they are also metabolized by P450s. Since P450s are hemoproteins, their induction and/or inhibition by chemical compounds could be coordinately accompanied by heme synthesis and/or inhibition. This review will take a retrospective view of research works carried out in our department and current findings on chemical-induced changes in hepatic heme metabolism in many places, together with current knowledge. Specifically, current beneficial aspects of induction of heme oxygenase-1, a rate-limiting heme degradation enzyme, and its relation to reciprocal and coordinated changes in P450s, with special reference to CYP2A5, in the liver are discussed. Mechanistic studies are also summarized in relation to current understanding on these aspects. Emphasis is also paid to an example of a single chemical compound that could cause various changes by mediating multiple signal transduction systems. Current toxicological studies have been developing by utilizing a sophisticated "omics" technology and survey integrated changes in the tissues produced by the administration of a chemical, even in time-and dose-dependent manners. Toxicological studies are generally carried out step by step to determine and elucidate mechanisms produced by drugs and chemicals. Such approaches are correct; however, current "omics" technology can clarify overall changes occurring in the cells and tissues after treating animals with drugs and chemicals, integrate them and discuss the results. In the present review, we will discuss chemical-induced similar changes of heme synthesis and degradation, and of P450s and finally convergence to similar or different directions.

show abstract

Protoporphyrin IX: the Good, the Bad, and the Ugly

Cited by 189 publications

References 155 publications

Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Chronic Treatment with Isoniazid Causes Protoporphyrin IX Accumulation in Mouse Liver

Chemical-induced coordinated and reciprocal changes in heme metabolism, cytochrome P450 synthesis and others in the liver of humans and rodents

Contact Info

Product

Resources

About